An observational study in Iris Tumor, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Oregon Health and Science University · Observational
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 100 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Oregon Health and Science University is the lead sponsor of 676 studies on the registry; 136 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 36 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults age 18 or older with either healthy eyes or iris tumors
Inclusion Criteria for tumor group:
Inclusion Criteria for healthy control group:
Exclusion Criteria (both groups):
This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
This group will consist of 50 adults age 18 and older who have healthy eyes.
Tumor Thickness in Benign vs Malignant Iris Lesions
OCT/OCTA will be used to compare tumor thickness measurements against the conventional Ultrasonic Biomicroscopy (UBM) device. Tumor thickness will be measured in millimeters, and growth of 0.5 mm or greater will be used to differentiate malignant from benign lesions.
Time frame: 6 months
Tumor Area in Benign vs Malignant Iris Lesions
Tumor area will be measured by OCT/OCTA in mm2 and compared against conventional UBM measurements.
Time frame: 6 months
Tumor Volume in Benign vs Malignant Iris Lesions
Tumor volume will be measured by OCT/OCTA in mm3 and compared against conventional UBM measurements.
Time frame: 6 months
Effect of Radiation Treatment on Tumor and Surrounding Ocular Structures
Vessel density and tortuosity will both be measured in % occupied by flow pixels on OCT/OCTA.
Time frame: 6 months after treatment
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Iris Neoplasms
Oregon Health and Science University